Abiopharma

🔍 Michael Edward L. (Director)

Company: QuidelOrtho Corp (QDEL)

Report Date: 2026-06-25

Detailed Transactions and Holdings:

• Acquired 15,532 shares of Restricted Stock Units (Equity Grant) (Derivative)
  Date: 2026-06-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 15,532.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Acquired 3,513 shares of Restricted Stock Units (Converted) (Derivative)
  Date: 2026-06-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,513.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Acquired 1,053 shares of Restricted Stock Units (Premium) (Derivative)
  Date: 2026-06-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,053.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2

Footnotes:

• F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
• F2: The restricted stock units will vest on June 25, 2027.
• F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule.
• F4: 878 shares vested on June 25, 2026, 878 shares will vest on September 25, 2026, 878 shares will vest on December 25, 2026, and 879 shares will vest on March 25, 2027.